Guinea pig models of COPD

  • Acute LPS exposure

    A feature of acute LPS exposure to the lungs is neutrophilic inflammation in the bronchoalveolar lavage fluid.
    Thus, effectiveness of your compound can be tested against this neutrophilic inflammation.
    We have previously demonstrated efficacy of anticholinergics and β2 agonists in this model. See publication

  • Chronic model with LPS exposure.

    Features of chronic LPS exposure to the lungs are:

    • Twice weekly LPS challenges for 12 weeks,
    • Tissue neutrophilia and cytokine production,
    • Collagen deposition around the small airways,
    • Mucus gland hypertrophy, goblet cell hyperplasia,
    • Right ventricle remodeling.

    We have previously shown efficacy of anticholinergics and GSK-3 inhibitors in this model. See publication

  • Guinea pig model of elastase-induced emphesyma

    Features:

    • Increase in mean linear intercept – emphysema,
    • Cytokine production in the lung,
    • Decrease in specific epithelial and endothelial cell markers. See publication

Mouse models of COPD

  • Mouse model of cigarette smoke-induced inflammation

    Features:

    • Infiltration of macrophages and neutrophils in the lung,
    • Cytokine production and growth factor release.

    We have previously shown efficacy of anticholinergics, in particular M3 selective anticholinergics, in this COPD mouse model.

  • Mouse model of elastase-induced emphysema

    Features:

    • Increase in mean linear intercept – emphysema,
    • Cytokine production in the lung,
    • Decrease in specific epithelial and endothelial cell markers. See publication

  • Mouse model of LPS exposure

    Features:

    • Infiltration of macrophages and neutrophils in the lung,
    • Cytokine production and growth factor release.